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Until now, April 22, 2020, Covid-19 has been 
confirmed in 2471136 patients and 203 countries 
and territories with mortality rate over 169000 
patients (1). Right now, there is no definite cure for 
it and developing treatments including vaccines 
and antiviral compounds are under evaluations 
for efficacy. COVID-19 infection can be mild, 
severe, or even critical. The symptoms may range 
from fever (the most common symptom), chills, 
fatigue and cough to decreased arterial oxygen 
saturation, changes in respiratory rate and 
dyspnea. The dyspnea in critically patients is more 
severe. In severe cases, respiratory failure, acute 
respiratory distress syndrome (ARDS) and septic 
shock have been reported. Septic shock is also 
associated with hypoxia and acidosis (2-4).  
ARDS is the most important cause of death in this 
group of patients. This feature of the disease may 
be caused by various factors, including 
inflammatory mediators and cytokine storm (5). 
The computed tomography (CT) imaging findings 
have shown that the lung with ARDS has a ground-
glass appearance, in which white fluid-filled 
patches are seen inside the lung. The fluid inside 
these patches has a jelly state (6, 7). Pathological 
samples obtained from lung tissue also indicate 
pulmonary damage, obvious destruction of 
pneumocytes and formation of a hyaluronan 
membrane, which more emphasized on ARDS 
occurrence (8). 
Cytokine storm caused by Covid-19 infection is a 
severe immune response. The occurrence of 
cytokine storm can lead to severe tissue damages. 
Pre-inflammatory factors are involved in this 
process and one of them is interleukin 6 (IL-6) 
which affects different cells. IL-6 performs various 
functions such as regulating body temperature, 
increasing the production of acute phase protein 
and differentiation of B cells (9). On the other hand, 
the production of interleukin 1 (IL-1) as an 
inflammatory mediator will be increased during 
cytokine storm, as well. IL-1 can cause fever and 
stimulating the production of hyaluronan which 
has been seen in fibrosis (10). Based on studies on 
SARS-CoV, rapid spread and proliferation of the 
virus as a result of delayed interferon-1 
production and subsequent rapid accumulation of 
macrophages and monocytes may also be involved 
in tissue destructions and a similar mechanism 
might be seen in COVID-19 infection (11). 
When there is no proper immune system 
response, the virus causes extensive tissue 
damages, especially to organs where ACE2 is most 
commonly seen, such as the lungs (7). Therefore, 
since the lungs are damaged, efforts should be 
focused on suppressing the inflammation, 
managing the symptoms and theoretically any 
compounds that may help this inflammation 
subside could play an important role in reducing 
the incidence of ARDS and consequently the 
mortality rate. 
The use of corticosteroids in different phases of 
ARDS has been inconsistent with conflicting 
results. Corticosteroids exert their anti-
inflammatory effects by regulating the signaling 
pathways on the membrane and inside the cells, 
stopping pre-inflammatory gene-related 
processes (genes responsible for producing pre-
inflammatory factors). Furthermore, they are able 
to increase the production of anti-inflammatory 
mediators such as interleukin 10 (IL-10) (12). 
Corticosteroids have been investigated in some 
clinical protocols for evaluation of their 
effectiveness in reducing inflammatory responses 
and cytokine storm. According to the guideline of 
World Health Organization (WHO), systemic 
corticosteroids should not be routinely used in 
viral pneumonia except in clinical trials. However, 
WHO has recommended that these compounds 
can be used in exacerbations of asthma and COPD, 
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and septic shock, considering each patient's 
condition and assessing the benefits and risks. 
This guideline further states that the use of 
corticosteroids in similar conditions such as 
influenza may lead to secondary super infections 
and increase mortality rate (13). But in another 
study on SARS-CoV, the use of corticosteroids was 
associated with improvement in time to survival 
in severe patients and decrease in mortality rate 
(14). Delayed viral clearance is another concern. In 
a study on patients with MERS-CoV, the use of 
corticosteroids did not make a significant 
difference in mortality rate. However, its 
association with a delay in viral clearance from the 
lungs of patients was reported (15). 
Side effects are another limiting factors for use of 
corticosteroids in patients with Covid-19. A 
similar study in patients with SARS-CoV showed 
that use of higher doses of corticosteroids in such 
conditions could cause a corticosteroid-induced 
diabetes, with 36.3% of patients experiencing 
such complication (16).  
The guideline of Surviving Sepsis Campaign for the 
management of patients with Covid-19 has 
recommended the use of corticosteroids under the 
following conditions: 1) in patients with Covid-19 
who are suffering from septic shock, the use of 
corticosteroids (low-dose) are preferred over not 
using it. The guideline notes that there is no 
difference in mortality rate and side effects. 
However, there is weak recommendation that 
using corticosteroids in these conditions can 
reduce the time of resolution of shock and ICU and 
hospital length of staying; 2) In cytokine storm, if 
the patient has not yet developed ARDS, 
corticosteroids are recommended in ways other 
than routine procedures, and if ARDS occurred, 
the use of these compounds is recommended over 
not using them. Lesser need of oxygen, improved 
radiographic findings and reduced length of 
staying in ICU and hospital are some of the 
advantages that this guideline has referred to. 
However, there is just a week recommendation 
over the use of these compounds in this guideline 
(17). 
Based on what has been discussed, it could be 
concluded that the use of corticosteroids in the 
current situation should be limited, since there are 
no significant benefits over their effectiveness. On 
the other hand, there is a risk in prolongation of 
viral clearance and secondary infections and 
mortality rate. The use of these compounds should 
be limited to clinical trials to further evaluate their 
effectiveness in this new found disease. The 
clinical conditions of patients should be carefully 
evaluated throughout the studies and close 
monitoring should be performed while 
discontinuing these drugs. 
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